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ABSTRACT 
Scope: The aim of the current study was to apply an untargeted metabolomics strategy to 
characterize a model of cocoa intake biomarkers in a free-living population. 
Methods and results: An untargeted HPLC-q-ToF-MS based metabolomics approach was 
applied to human urine from 32 consumers of cocoa or derived products (CC) and 32 matched 
control subjects with no consumption of cocoa products (NC). The multivariate statistical 
analysis (OSC-PLS-DA) showed clear differences between CC and NC groups. The 
discriminant biomarkers identified were mainly related to the metabolic pathways of 
theobromine and polyphenols, as well as to cocoa processing. Consumption of cocoa products 
was also associated with reduced urinary excretions of methylglutarylcarnitine, which could be 
related to effects of cocoa exposure on insulin resistance. To improve the prediction of cocoa 
consumption, a combined urinary metabolite model was constructed. ROC curves were 
performed to evaluate the model and individual metabolites. The AUC values (95% CI) for the 
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model were 95.7% (89.8–100%) and 92.6% (81.9–100%) in training and validation sets, 
respectively, whereas the AUCs for individual metabolites were <90%. 
Conclusions: The metabolic signature of cocoa consumption in free-living subjects reveals that 
combining different metabolites as biomarker models improves prediction of dietary exposure 
to cocoa. 
 
Abbreviations: AUC, area under the curve; CC, cocoa consumers; FFQ, food-frequency 
questionnaire; MVA, multivariate analyses; NC, nonconsumers of cocoa; OSC-PLS-DA, 
partial least squares discriminant analysis with orthogonal signal correction; ROC, receiver 
operating curve; VIP, variable importance for projection 
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1. INTRODUCTION 
Due to the complexity and limitations of traditional dietary assessment tools, in addition to their 
inherited measurement biases, there is a growing interest in the implementation of dietary 
biomarkers in nutritional epidemiology as objective measures of dietary exposure [1]. Recently, 
the food metabolome has been proposed as a novel data-driven approach to improve dietary 
consumption measurements and uncover new food biomarkers [2]. Biomarkers of dietary 
consumption are defined as the compounds characteristic of a dietary constituent that 
discriminate consumers from nonconsumers [1]. However, most food constituents are broadly 
present in different foods, hence they are not unique to a specific food item. This fact adds 
complexity to the discovery of new food biomarkers and means that only a few compounds can 
be considered as biomarkers of a particular dietary constituent, such as proline betaine for the 
consumption of citrus fruits [3] or resveratrol for wine [4]. To overcome this issue, a 
combination of food-derived metabolites could provide a more accurate and precise 
measurement of consumption. However, this field has been practically unexplored for the 
discovery of dietary biomarkers [2]. 
There is a growing body of evidence on the beneficial health effects of cocoa consumption, 
especially in relation to cardiovascular diseases [5]. To better examine the link between cocoa 
consumption and health outcomes, an accurate and objective assessment of dietary exposure to 
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cocoa products is required. Various controlled dietary intervention studies have used both 
untargeted [6-8] and targeted approaches [9-11] on urinary excretion profiles associated with 
acute and chronic cocoa interventions and reported host and microbiota metabolites as 
conventional candidates for biomarkers of cocoa consumption. Nevertheless, not all of the 
proposed cocoa consumption biomarkers have been studied in populations under free-living 
conditions. Although some studies on dietary patterns [12] and food items [3, 13, 14] have 
already been conducted in free-living subjects, to our knowledge no study has evaluated the 
urinary metabolome of habitual cocoa consumers in a free-living population. This kind of study 
could provide more realistic data about differences in metabolome according to habitual cocoa 
consumption. 
In this context, the aim of the current study was to apply a metabolomics strategy to develop a 
potential model of cocoa intake biomarkers in a free-living population not submitted to dietary 
recommendations. 
 
2. MATERIALS AND METHODS 
The present report was designed and conducted as a cross-sectional study using baseline data 
and urine samples of 275 participants from the PREDIMED study. 
 
2.1. The PREDIMED study 
The PREDIMED study was a large, parallel-group, multicentre, randomized, and controlled 
clinical trial (ISRCTN 35739639; http://www.predimed.org). It was designed to assess the 
effects of the Mediterranean diet on the primary prevention of cardiovascular diseases in a high-
risk population. The details of the trial have been published elsewhere [15]. Briefly, participants 
were men (55–80 years) and women (60–80 years) with no cardiovascular disease at enrolment 
and fulfilling at least one of the two following criteria: presence of type 2 diabetes mellitus or 
at least three conventional cardiovascular risk factors [15]. The samples used in the present 
study were baseline spot urines collected and stored according to the PREDIMED study 
protocol. In parallel to these, dieticians administered to participants a validated semiquantitative 
137-item food-frequency questionnaire (FFQ) [15]. The PREDIMED trial protocol was 
conducted according to the Declaration of Helsinki and was approved by the institutional 
review boards of all the centres involved. All participants provided written informed consent. 
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2.2. Sample selection according to cocoa consumption 
In order to assess the biomarkers of cocoa exposure by a metabolomics approach, baseline urine 
samples from three PREDIMED trial centres (Barcelona, Valencia, and Navarra) were matched 
to corresponding individual FFQ data. Two cocoa consumer groups were formed: (i) 
nonconsumers (NC), i.e., individuals who never consumed any (0 g/day) of three FFQ-defined 
cocoa-containing food items: chocolate, cocoa powder or chocolate chip cookies; and (ii) cocoa 
consumers (CC), i.e., subjects with consumption of at least three servings/week of chocolate 
(serving size, 30 g) and/or cocoa powder (serving size, 5g), whereas chocolate cookie 
consumption was not taken into consideration in this second group due to the very low amount 
of cocoa per serving. There were 32 subjects defined as CC and 192 defined as NC (the other 
51 participants did not fulfil any criteria from both cocoa consumer groups). In order to reduce 
the potential sources of variability not related to cocoa exposure, one NC was selected for each 
CC. NC subjects were matched to CC subjects by sex (male or female), age (≤67 or >67 years), 
energy intake (≤2000 or >2000 kcal), and centre (Barcelona, Valencia or Navarra). 
Furthermore, the two groups had to be homogeneous regarding body mass index, leisure time 
physical activity, smoking habit, diabetes status, presence of hypertension and dyslipidaemia, 
and use of insulin, oral antidiabetics, lipid-lowering drugs and antihypertensive drugs. 
 
2.3. Sample preparation, HPLC-q-ToF-MS analysis, and data acquisition 
Sample preparation and data acquisition was based on methodology previously published by 
our group [6, 7]. HPLC-q-ToF-MS analyses were performed using an Agilent 1200 Series 
Rapid Resolution HPLC system coupled to a hybrid quadrupole TOF (QTOF) QSTAR Elite 
(AB Sciex). 
 
2.4. Data processing 
The HPLC-q-ToF-MS raw data were extracted and aligned using MarkerView TM 1.2.1. 
software (AB Sciex; Toronto, Ontario, Canada). Data from negative and positive ionization 
modes were included in two separate data sets in order to analyze them individually. Peak 
detection was performed as specified elsewhere [6, 7]. A 0.05 Da mass tolerance range was 
used for alignment. RT tolerance windows were 0.10 and 0.14 min for negative and positive 
ionization mode data sets, respectively. Mass features that were missing in at least 20% of 
samples from both groups were considered to be noise and excluded from further analyses [16]. 
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2.5. Data analyses and biomarker selection: Metabolic profiling differentiation 
Principal component analysis was applied to evaluate the quality of the data acquisition. 
Multivariate analyses (MVA) were performed using SIMCA-P+ 13.0 software (Umetrics, 
Umeå Sweden). Partial least squares discriminant analysis with orthogonal signal correction 
(OSC-PLS-DA) was used to examine between-group differences. As this study involved 
samples from free-living subjects, OSC filtration was applied to reduce the variability not 
associated with dietary classification, i.e., differences in lifestyle, dietary habits or drug 
prescriptions within the given population in the days before sample collection [13]. The data 
set was log-transformed and Pareto-scaled prior to MVA. The quality of the models was 
evaluated by R2Y(cum) and Q2(cum) parameters. Model validation was evaluated by a 
permutation test (n = 200). Those variables with the highest variable importance for projection 
(VIP) values (cut-off ≥1.5) were selected as the most relevant to explain the differences in 
metabolic profile. In parallel, Mann–Whitney analysis or independent sample t-test were 
performed on the OSC filtered dataset, according to their distribution. The Kolmogorov–
Smirnov test was used to check data distribution. 
 
2.6. Identification of metabolites 
A method combining computational-assisted metabolite identification and LC-MS profile 
analysis was applied [6, 7] on the basis of exact mass (±5 mDa), which was compared to those 
registered in HMDB, KEGG, and METLIN. In addition, an in-house database focused on 
cocoa-derived metabolites was employed [6, 7] using an automated identification algorithm 
implemented in an R package [17]. The biological interpretation was performed using 
information from relevant scientific bibliographies and online databases such as HMDB and 
KEGG. 
 
2.7. Venn diagram 
A Venn diagram was created [18] in order to plot which identified metabolites overlapped with 
previous studies from our group on biomarkers of cocoa exposure with different study designs 
[6, 7]. 
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2.8. Developing models of combined urinary markers 
We designed a prediction model and constructed receiver operating characteristic (ROC) curves 
to evaluate the accuracy of the model and of each discriminatory metabolite using filtered data 
from the OSC-PLS-DA analysis. 
First, the data set was randomly split into two-thirds for training (n = 42) and one-third for 
validation sets (n = 22). Then, a forward stepwise logistic regression model was constructed on 
the training sample set in order to design the best combination of metabolites for cocoa 
consumption prediction. This analysis was conducted using IBM SPSS Statistics 20 software 
(SPSS Inc., Chicago, IL, USA). The model was constructed employing the dichotomous 
variable of cocoa consumption (yes/no) as dependent variable and those metabolites which 
overlapped in the three studies according to the results of the Venn diagram as independent 
variables (continuous).The correlation between cocoa intake and the combined model was 
evaluated using Spearman's rank correlation coefficient. 
ROC curves were used to evaluate the accuracy of this model, in addition to separate evaluation 
of discriminatory metabolites individually [19]. ROC curve analyses for the designed model 
were performed in training and in validation sets to evaluate the combined model and in the 
whole population when assessing individual metabolites. The global performance of each 
metabolite and biomarker model was evaluated by the area under the ROC curve (AUC) and 
by the determination of sensitivity and specificity at the optimal cut-off point defined by the 
minimum distance to the top-left corner. 
 
3. RESULTS AND DISCUSSION 
The mean (±SD) cocoa consumption of the consumer group was 18.3 ± 13.4 g/day. The subjects 
included were 18 (28.1%) men and 46 (71.9%) women, with age 67.0 ± 6.3 years and BMI 29.8 
± 3.7 kg/m2. 
 
3.1. MVA of urinary metabolomic profiles 
The principal component analysis of urine samples revealed that they were not clustered 
according to the order of injection (Supporting Information Fig. 1). The OSC-PLS-DA analysis 
resulted in two one-component models with satisfactory modeling and prediction results, 
indicating that both models were able to discriminate the cocoa consumption group. The quality 
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parameters of both OSC-PLS-DA models are summarized in Table 1. The obtained models 
were well validated by a permutation test [13]. 
Table 1. Summary of parameters for assessing the OSC-PLS-DA modeling quality 
 OSC-PLS-DA Permutation test (n = 200) 
  R2Y (cum) Q2Y (cum) R intercept Q intercept 
Negative Mode 0.954 0.702 0.669 ‒0.140 
Positive Mode 0.947 0.723 0.627 ‒0.159 
 
3.2. Metabolic footprint of cocoa product exposure 
In order to select those markers with the largest contributions to the difference in urinary 
metabolome of each cocoa consumption group, VIP ≥1.5 was considered as the cut-off value. 
Based on this, we identified a total of 31 discriminating metabolites, as listed in Table 2. This 
table includes information about retention time, detected mass, and putative identifications of 
metabolites. Further information about statistical significance (p-value), VIP-values, mean of 
feature intensities from raw data, and the percentages of samples in which the feature was 
detected is provided by Supporting Information Table 1. 
Cocoa products such as chocolate are important sources of phytochemicals, mainly polyphenols 
(flavan-3-ols), and purine alkaloids (theobromine) [8]. Additionally, cocoa manufacturing 
procedures, such as roasting or fermentation, alter its composition by incorporating new 
compounds. In this context, the obtained results are in accordance with previous controlled 
dietary intervention studies, in which different compounds derived from theobromine and 
polyphenol metabolism, manufacturing processes, and acylcarnitine pathways were identified 
[6, 7]. In particular, in the CC group there were higher urinary excretions of xanthine, 5-
acetylamino-6-amino-3-methyluracil (AMMU), 3-methyluric acid, 7- and 3-methylxanthine, 
3,7-dimethyluric acid, and theobromine. With regard to polyphenols, both host (epicatechin and 
vanillin metabolites) and microbial (hydroxyphenylvalerolactones and hydroxyphenylvaleric 
acids) metabolites were tentatively identified. Additionally, processing-derived compounds 
were also characteristic of the CC group. Levels of aspartyl-phenylalanine and cyclo(aspartyl-
phenylalanil) were also elevated in the CC group. Cyclo(aspartyl-phenylalanil) is a constituent 
of roasted cocoa nibs (metabocard HMDB31360). Furthermore, both compounds are 
degradation products of aspartame. Furoylglycine is a derivative of furan, which is a compound 
detected in roasted cocoa [20]. 
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Table 2. Discriminating metabolites between nonconsumers and consumers of cocoa 
products 
CC 
versus 
NCa 
RT Metabolite Detected mass [Assignation] 
Theobromine metabolism 
↑ 0.63 Xanthine 151.0259 [M – H]– 
↑ 0.67 AMMU 199.0816 [M + H]+; 221.0637 [M + Na]+; 237.0376 [M + K]+; 171.0865 [M + 
H – CO]+; 172.0882 13C[M + H – CO]+; 156.0629 [M + H – C2H3O]+ 
↑ 0.87 AMMU isomer 199.0785 [M + H]+; 237.0375 [M + K]+; 171.0861 [M + H – CO]+; 156.0625 
[M + H – C2H3O]+ 
↑ 1.13 3-Methyluric acid 181.0328 [M – H]–; 363.0787 [2M – H]–; 364.0806 13C[2M – H]–; 166.0121 
[M – H – CH3]–; 183.0509 [M + H]+ 
↑ 1.37 7-Methylxanthine 167.0568 [M + H]+; 168.0574 13C[M + H]+; 189.0355 [M + Na]+; 333.1059 
[2M + H]+; 124.0499 [M + H – CHNO]+ 
↑ 1.62 3-Methylxanthine 165.0416 [M – H]–; 166.0422 13C[M – H]–; 122.0347 [M – H – CHNO]–; 
167.0597 [M + H]+; 168.0580 13C[M + H]+; 189.0371 [M + Na]+ 
↑ 1.85 3,7-Dimethyluric acid 195.0500 [M – H]–; 196.0527 13C[M – H]–; 180.0273 [M – H – CH3]–; 
197.0678 [M + H]+ 
↑ 2.75 Theobromine 181.0707 [M + H]+; 138.0660 [M + H – CHNO]+ 
Cocoa taste and flavor 
↑ 1.88 Furoylglycine 170.0449 [M + H]+; 95.0132 [M + H – glycine]+ 
↑ 4.72 Cyclo(aspartyl-
phenylalanyl) 
261.0872 [M – H]– 
↑ 4.73 Aspartyl-phenylalanine 279.0943 [M – H]–; 280.1001 13C[M – H]–; 281.1135 [M + H]+; 133.0629 [M 
+ H – C9H8O2]+ Host polyphenol metabolism 
↑ 4.38 Vanillin sulphate 230.9982 [M – H]–; 151.0385 [M – H – sulphate]– 
↑ 4.48 (Epi)catechinglucuronide 465.1013 [M – H]– 
↑ 4.85 Vanillic acid 167.0365 [M – H]– 
↑ 5.37 (Epi)catechin sulphate 369.0252 [M – H]– 
Microbial polyphenol metabolism 
↑ 3.73 HDHPVA glucuronide 401.1072 [M – H]– 
↑ 3.90 HHMPVA glucuronide 415.1237 [M – H]–; 416.1270 13C[M – H]– 
↑ 3.90 MHPV 223.0925 [M + H]+ 
↑ 4.15 DHPV sulfoglucuronide 287.0229 [M – H – glucuronide]– 
↑ 4.20 DHPV glucuronide 383.1005 [M – H]–; 384.1038 13C[M – H]–; 402.1398 [M + NH4]+; 209.0795 
[M + H – glucuronide]+ 
↑ 4.30 HDHPVA 225.0736 [M – H]–; 226.0788 13C[M – H]–; 101.0229 [M – H – C7H8O2]– 
↑ 4.37 HDHPVA sulphate 305.0291 [M – H]– 
↑ 4.42 DHPV glucuronide 383.0972 [M – H]–; 384.1004 13C[M – H]–; 385.1105 [M + H]+; 209.0785 [M 
+ H – glucuronide]+ 
↑ 4.60 HHMPVA sulphate 319.0495 [M – H]– 
↑ 4.60 MHPV glucuronide 397.1101 [M – H]–; 221.0776 [M – H – glucuronide]–; 416.1513 [M + NH4]+; 
223.0932 [M + H – glucuronide]+ 
↑ 4.70 HPV glucuronide 367.0990 [M – H]–; 368.1021 13C[M – H]– 
↑ 5.22 DHPV sulphate 207.0638 [M – H – sulphate]–; 289.0343 [M + H]+; 131.0446 [M + H – 
sulphate – 2(H2O) – C2H2O]+ 
↑ 5.62 HPV sulphate 191.0678 [M – H – sulphate]– 
↑ 6.54 HHPVA acid sulphate 289.0391 [M – H]–; 290.0425 13C[M – H]–; 209.0788 [M – H – sulphate]–; 
210.0852 13C[M – H – sulphate] – 
↑ 6.64 HPVA sulphate 273.0454 [M – H]–; 274.0489 13C[M – H]–; 193.0886 [M – H – sulphate]–; 
194.0911 13C[M – H – sulphate]– Acylcarnitine pathway 
↓ 1.87 Methylglutarylcarnitine 290.1590 [M + H]+; 291.1625 13C[M + H]+; 144.0982 [M + H – C6H10O4]+; 
129.0545 [M + H – carnitine]+; 101.0590 [M + H – carnitine – CO]+ 
AMMU, 6-Amino-5[N-methylformylamino]-1-methyluracil; DHPV, 5-(3′,4′-dihydroxyphenyl)-valerolactone; HDHPVA, 4-
Hydroxy-5-(dihydroxyphenyl)-valeric acid; HHMPVA, 4-Hydroxy-5-(hydroxy-methoxyphenyl)-valeric acid; HHPVA, 4-
Hydroxy-5-(hydroxyphenyl)-valeric; HPV, Hydroxyphenyl-valerolactone; HPVA, 4-Hydroxy-5-(phenyl)-valeric acid; 
MHPV, Methoxyhydroxyphenylvalerolactone; RT, retention time. 
aRows indicate levels in consumers of cocoa products versus nonconsumers: ↑ and ↓ means higher and lower levels, 
respectively, in cocoa consumers. 
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With respect to the endogenous metabolome, methylglutarylcarnitine showed reduced levels 
associated with habitual cocoa consumption. This metabolite belongs to the acylcarnitine class 
of compounds. Mass spectra of this metabolite is shown in Supporting Information Fig. 2. 
Fragments include the neutral loss of 77 and 161 amu corresponding to the loss of the 
trimethylamine moiety in addition to a loss of H2O and the loss of the carnitine backbone, 
respectively, as well as, the common fragments of the acylcarnitine family at m/z 85 and 144 
[21]. The protonated molecule of methylglutarylcarnitine was observed in all samples in both 
groups, but was significantly more abundant in the NC group (Supporting Information Table 
1). Zuniga and Li (2011) published the most comprehensive acylcarnitine profile in urine [21]. 
It was composed by a wide range of molecules with different chain lengths. Acylcarnitines are 
involved in mitochondrial lipid oxidation. They are originated from the conjugation of carnitine 
with fatty acids and promote fatty acid transport into the mitochondrial matrix for β-oxidation. 
The accumulation of these compounds has been related to insulin resistance through alterations 
in fatty acid β-oxidation in insulin-sensitive tissues, such as skeletal muscle [22]. In line with 
the present results, dark chocolate intake was previously associated with reduced levels of 
methylglutarylcarnitine together with other acylcarnitinies [8]. Indeed, this observation could 
reflect a potential mechanism of action for previously observed associations between chocolate 
or cocoa intake and improved insulin resistance [23]. 
 
3.3 Discriminant biomarkers of cocoa exposure replicated in studies with different designs 
A large proportion of all identified metabolites characteristic of habitual cocoa product 
exposure under free-living conditions matched with biomarkers of cocoa intake previously 
proposed by our research group using different study designs [6, 7]. Figure 1 illustrates a Venn 
diagram that shows that ten metabolites were characteristic of cocoa exposure independently of 
the study design. They were characteristic of theobromine metabolism (AMMU, 3-methyluric 
acid, 7- and 3-methylxanthine, 3,7-dimethyluric acid and theobromine) as well as polyphenol 
microbial metabolites (methoxyhydroxyphenylvalerolactone, and glucuronide and sulphate 
conjugates of 5-(3′,4′-dihydroxyphenyl)-valerolactone). All of these compounds can be 
considered as medium-term markers of cocoa intake: theobromine-derived metabolites have 
been detected over a 24 h period [6, 24] and polyphenol metabolites derived from microbial 
metabolism are excreted after those derived from metabolism by host tissues [6]. Thus, these 
results reinforce the concept that, in free-living populations, slowly excreted compounds could 
be better biomarkers than those that are rapidly excreted [13]. 
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Figure 1. Venn diagram showing overlapping and unique metabolites associated with 
cocoa consumption for the three types of study. 
 
 
With this study we have completed the pipeline recently proposed by Heinzmann et al. [3] and 
Pujos-Guillot et al. [13], in which three studies with different designs were developed in order 
to discover biomarkers of dietary exposure. First, we conducted an acute study in which urine 
samples from ten volunteers who randomly consumed either a single dose of cocoa powder 
with milk or water, or milk without cocoa, were collected before and at different times during 
a 24 h period after the ingestion of the test meal, and were analyzed through untargeted 
metabolomics. In this study, 27 compounds were linked to cocoa consumption [6]. 
Subsequently, we performed a 4 wk crossover dietary intervention study with 20 subjects who 
received cocoa powder with skimmed milk or milk alone. After the analysis of 24 h urine 
samples from baseline and at the end of the intervention by the same untargeted metabolomics 
approach, 42 metabolites were identified as the most discriminating of regular cocoa 
consumption [7]. Finally, in the present study we examined the differences in urinary 
metabolome between individuals who reported regular consumption of cocoa products and 
those who reported no consumption. After the untargeted metabolomics analysis, we identified 
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a total of 31 discriminating metabolites. Ten of them have been reported in both previous 
studies, thus they could be the best candidates for biomarkers of cocoa consumption (Fig. 1). 
The reason for some metabolites not being shared among the three types of studies could be a 
different level of control of the diet and other lifestyle variables, the heterogeneity of the study 
population, the type of biological sample used or the amount of cocoa products ingested. 
Interestingly, the ten overlapping compounds remained discriminative of cocoa exposure in 
both middle-aged and older adults, as well as in healthy and high-cardiovascular risk 
individuals. Additionally, in the dietary intervention studies, the other sources of polyphenols 
were avoided during the days prior to the intervention, but subjects included in this analysis 
followed their habitual dietary habits, that is, these metabolites remained characteristic of cocoa 
consumption despite the fact that no dietary restriction was enforced prior to sample collection. 
Regarding the type of biological samples used, they were different in each study. In the first 
acute study urine samples were obtained before consumption and 6, 12 and 24 h after cocoa 
intake [6]. In the second study, 24 h urine samples were used [7] since they have been described 
as the best method for monitoring daily intake [25]. However, the collection of 24 h urines 
samples is impractical in large-scale epidemiological studies [25]. For that reason, the 
replication of these metabolites using spot urines from free-living subjects, as those from the 
present study, reinforces their discriminatory power for exposure to cocoa products. Finally, 
different amounts of cocoa were consumed: in the acute study, subjects received 40 g of cocoa 
powder, while in the long-term intervention trial, volunteers consumed two sachets/day of 20 g 
of cocoa powder. However, in the present study we still observed differential urinary 
metabolomic profiles explained by the same classes of metabolites despite the fact that the study 
subjects had weekly exposure to cocoa products. Because the proposed biomarkers have 
remained differential with the habitual amount of cocoa consumption and morning spot urines 
have been used, our results support the application of this metabolomic approach to other 
nutritional epidemiologic studies. 
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3.4 Proposed model of combined urinary metabolites as a new biomarker of intake 
To improve the prediction of cocoa product exposure, a combination of more than one 
discriminatory metabolite was developed using the training set (Table 3). For this analysis, we 
considered those metabolites that were common to the three types of studies (Fig. 1). Because 
all overlapping metabolites were detected in positive ionization mode, the data set with this 
type of data was used. As a result, the model included 7-methylxanthine and 5-(3′,4′-
dihydroxyphenyl)-valerolactone glucuronide. Reported daily cocoa product consumption 
correlated [r (95% CI)] significantly with values of the combined model [r = 0.74 (0.61-0.83); 
p < 0.001]. The performance of the designed model was evaluated by the AUC in both training 
and validation sets (Fig. 2). We also constructed ROC curves for the ten overlapping 
metabolites independently. Table 4 shows that the combination of metabolites is a better 
discriminator (AUC > 90% in both training and validation sets) than each metabolite 
individually (AUC < 90% in all cases), reinforcing the improved capacity of biomarker patterns 
to distinguish between different dietary exposures. It is important to note that one component 
of theobromine metabolism together with another from polyphenol microbiota metabolism 
were present in the combined model. Any of the other eight metabolites did not enter the model, 
probably as a result of colinearity in the information provided by these compounds. We 
hypothesize that this could be because all of those from the same metabolic pathways give 
similar biological or dietary information and when one is introduced in the model the others do 
not provide more relevant information. Thus, the two metabolites contributed to the combined 
model, giving complementary information about habitual cocoa intake. 
 
Table 3. Metabolites selected by stepwise logistic regression model for the 
discrimination of cocoa product consumption using the training set 
Metabolite Coefficient Standard error p-value 
7-Methylxanthine 5.563 1.899 0.003 
DHPV glucuronide 4.081 1.559 0.009 
DHPV, 5-(3′,4′-dihydroxyphenyl)-valerolactone. 
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Figure 2. Receiver operating characteristic (ROC) curves of the combined urinary 
metabolite model in the training and validation sets. 
 
 
Table 4. Receiver operating characteristic (ROC) curve parameters of the combined 
urinary metabolite model in the training and validation sets and of overlapping 
discriminatory metabolites in the three types of study among all population 
   
Specificity 
(%) 
Sensitivity 
(%) 
AUC (95% CI) 
Combined model Training set 90.5 90.5 95.7 (89.8–100) 
  Validation set 81.8 90.9 92.6 (81.9–100) 
AMMU  81.3 87.5 88.2 (79.5–96.9) 
AMMU isomer  71.9 71.9 76.7 (65.1–88.3) 
3-Methyluric acid  78.1 78.1 82.2 (71.2–93.2) 
7-Methylxanthine  87.5 78.1 88.3 (80.1–96.5) 
3-Methylxanthine  81.3 81.3 85.2 (75.6–94.7) 
3,7-Dimethyluric acid  78.1 81.3 83.6 (73.3–93.9) 
Theobromine  68.7 78.1 69.8 (56.5–83.2) 
Methoxyhydroxyphenylvalerolactone 71.9 71.9 73.4 (60.6–86.2) 
DHPV glucuronide  59.4 78.1 68.3 (55.0–81.5) 
DHPV sulphate   75.0 62.5 71.1 (58.3–83.9) 
 
  
14 
4. CONCLUDING REMARKS 
In the current study we applied an untargeted metabolomics strategy to discriminate the urinary 
metabolome of regular cocoa product consumers in a free-living population. This approach 
revealed a number of metabolites, most of which have already been detected in other controlled 
cocoa dietary intervention studies. The fact that some of them are produced by the gut 
microbiota reinforces the hypothesis that the microbial food metabolome is an important source 
of dietary biomarkers. Interestingly, an acylcarnitine metabolite was inversely associated with 
cocoa intake. Because of the potential role of this class of compounds in insulin resistance, this 
observation could provide a mechanistic insight into the beneficial effects of cocoa 
consumption on insulin sensitivity previously described in epidemiological studies. 
Additionally, we developed a combined model of urinary metabolites that could be used as a 
more accurate tool for the discrimination of cocoa consumers in epidemiological studies. With 
this report, one more step has been taken in the research on dietary biomarkers. Until now, the 
study of food metabolome in the discovery of biomarkers of dietary consumption has focused 
mainly on changes and differences in individual metabolites. Here we show that combining 
different metabolites improves measurements of dietary exposure to cocoa products. These 
findings should be further validated in a wider cohort. We anticipate that this approach might 
also be successfully applied in the evaluation of complex dietary patterns, composed of distinct 
food items. Finally, the nature of this study adds complementary information about the 
metabolic footprint of a cocoa consumption closer to the real conditions encountered in 
epidemiological studies, which deal mostly with free-living subjects without any dietary 
restriction or specific supplementation. 
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